Wockhardt Limited (BOM:532300)

India flag India · Delayed Price · Currency is INR
1,478.45
+12.10 (0.83%)
At close: Aug 22, 2025
0.83%
Market Cap231.96B
Revenue (ttm)30.34B
Net Income (ttm)-1.23B
Shares Outn/a
EPS (ttm)-7.68
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume22,944
Average Volume30,118
Open1,455.00
Previous Close1,466.35
Day's Range1,454.05 - 1,483.70
52-Week Range918.85 - 1,870.00
Betan/a
RSI33.50
Earnings DateAug 8, 2025

About Wockhardt

Wockhardt Limited, together with its subsidiaries, operates as a pharmaceutical and biotech company, in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. It manufactures and trades pharmaceuticals, medicinal chemical, and botanical products, as well as chemicals and chemical products. The company also develops its flagship antibiotic, ZAYNICH zidebactam/cefepime, a novel beta lactam enhancer mechanism for the treatment of sepsis and hospital/ventilator associated pneumonia; FOVISCU, an anti... [Read more]

Industry Pharmaceutical Preparations
Founded 1967
Employees 2,296
Stock Exchange Bombay Stock Exchange
Ticker Symbol 532300
Full Company Profile

Financial Performance

In 2024, Wockhardt's revenue was 30.35 billion, an increase of 7.24% compared to the previous year's 28.30 billion. Losses were -470.00 million, -89.85% less than in 2023.

Financial Statements

News

There is no news available yet.